MEA Peptic Ulcer Drugs Market

MEA Peptic Ulcer Drugs Market Size (2024 to 2029)

The Middle East & Africa Peptic ulcer drugs Market was worth USD 0.27 billion in 2024 and is estimated to be growing at a CAGR of 0.99%, to reach USD 0.28 billion by 2029.

A peptic ulcer is a breakage in the inner surface of the stomach or the upper part of the intestine in the gastrointestinal tract. Ulcers form when the protective wall of the intestine or stomach is broken.

The MEA peptic ulcer drug market is expected to grow at a gradual rate in the coming years, due to increasing patient awareness of the easy availability of effective drugs for peptic ulcers. In addition, the increasing preference of patients for the consumption of drugs due to increased effectiveness should encourage the drug manufacturers to develop new drugs in the years to come. Products with lesser side effects and research and developments especially in medical institutions and hospitals will support the market in the MEA region.

There is an increasing rate of chronic disease patients such as Irritable Bowel Syndrome, cancer, muscular-skeletal diseases which required long-term and heavy use of pain-relieving medications. Factors such as the higher cost of alternative treatment to tackle peptic ulcers, improvements in healthcare infrastructure, and increased funding by government agencies of the healthcare system are driving the growth of the drug market for peptic ulcer disease in the MEA region. Increasing in the number of patients developing quadruple bismuth therapy, the change in lifestyle and diet, the growing inclination towards generics are expected to boost the MEA market and provide lucrative opportunities for the major players in the years to come.

However, Factors such as the increased adverse effects of proton pump inhibitors, expiration of patents for various drugs due to their effectiveness are expected to restraint the MEA market growth rate.

This research report on the MEA peptic ulcer drugs market has been segmented and sub-segmented into the following categories

MEA Peptic Ulcer Drugs Market Analysis By Drug Type

• Proton Pump Inhibitors (PPIs)
• Anti-Histamines
• H2 Antagonists
• Antacids
• Antibiotics
• Others

MEA Peptic Ulcer Drugs Market Analysis By Ulcer Type

• Gastric Ulcers
• Duodenal Ulcer
• Esophageal Ulcer

MEA Peptic Ulcer Drugs Market Analysis By Country

• KSA

• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The MEA peptic ulcer drugs market is leading and this is analyzed to remain dominant throughout the forecast period. The growing incidence of people with peptic ulcers is one of the key factors that should drive the development of the Middle East market in the years to come. The growing incidence of peptic ulcers is encouraging companies to market and produce peptic ulcer drugs in MEA, particularly in Saudi Arabia, UAE, and Qatar.

In addition, Saudi Arabia and the UAE will achieve a substantial share of the MEA market in the near future. A large number of patents that may expire, allowing the entry of generics, are expected to drive MEA market growth. In contrast, emerging economies in African region in the Middle East and Asia are expected to experience good growth during the forecast period. The increasing demand for peptic ulcer drugs due to poor hygiene and disinfection leading to H. pylori among the inhabitants of these regions is the key factor that is expected to boost the market for peptic ulcer drugs market over the next few years.

Saudi Arabia will be the largest revenue-generating regional market for peptic ulcer drugs due to more affected people, improved diagnostic techniques, high healthcare awareness, and increased awareness of peptic ulcer disease. Other regions such as Kuwait, Bahrain, Oman, and Egypt are expected to gather good market revenues during the projected period. South Africa will grow at a good CAGR during the forecast period owing to the population, developing economic conditions, and improving health infrastructure in the region.

KEY MARKET PLAYERS

Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc., Helicure AB and Eumedica Pharmaceuticals are some of the companies currently dominating the MEA peptic ulcer drugs market and profiled in this report.